Feinberg W M, Cornell E S, Nightingale S D, Pearce L A, Tracy R P, Hart R G, Bovill E G
Department of Neurology, University of Arizona Health Sciences Center, Tucson, USA.
Stroke. 1997 Jun;28(6):1101-6. doi: 10.1161/01.str.28.6.1101.
The prothrombin time (expressed as the international normalized ratio [INR]) is the standard method of monitoring warfarin therapy in patients with atrial fibrillation. Prothrombin activation fragment F1.2 provides an index of in vivo thrombin generation and might provide a better index of the effective intensity of anticoagulation. We examined the relationship between F1.2 and INR in patients with atrial fibrillation.
We measured INR and F1.2 levels in 846 patients with atrial fibrillation participating in the Stroke Prevention in Atrial Fibrillation III study. Two hundred nineteen (26%) were taking aspirin alone, 326 (39%) were taking adjusted-dose warfarin, and 301 (36%) were taking a low fixed dose of warfarin (1 to 3 mg) plus aspirin (combination therapy). F1.2 levels were measured with an enzyme-linked immunosorbent assay.
Patients receiving adjusted-dose warfarin or combination therapy had significantly higher INR and significantly lower F1.2 values than those on aspirin alone (P < or = .0001 for each of the four comparisons). F1.2 values (nanomolar) were inversely correlated with INR (F1.2 = -0.1 + 2.3[1/INR]; R2 = .37; P < .0001; simple linear regression). However, significant variability remained. Among patients receiving warfarin, older patients had higher F1.2 values than younger patients after adjustment for INR intensity (P < .001) in the model. There was no difference in the relationship between F1.2 and INR between men and women.
Increasing intensity of anticoagulation, as measured by the INR, is associated with decreasing thrombin generation as measured by the F1.2 level, but significant variability exists in this relationship. Older anticoagulated patients have higher F1.2 values than younger patients at equivalent INR values. The clinical significance of these differences is not clear. F1.2 measurement might provide information regarding anticoagulation intensity in addition to that reflected by the INR.
凝血酶原时间(以国际标准化比值[INR]表示)是监测心房颤动患者华法林治疗的标准方法。凝血酶原激活片段F1.2可反映体内凝血酶生成情况,可能是更好的抗凝有效强度指标。我们研究了心房颤动患者中F1.2与INR之间的关系。
我们测量了参与心房颤动预防卒中III研究的846例心房颤动患者的INR和F1.2水平。219例(26%)仅服用阿司匹林,326例(39%)服用调整剂量的华法林,301例(36%)服用低固定剂量的华法林(1至3毫克)加阿司匹林(联合治疗)。采用酶联免疫吸附测定法测量F1.2水平。
接受调整剂量华法林或联合治疗的患者的INR显著高于仅服用阿司匹林的患者,F1.2值显著低于仅服用阿司匹林的患者(四项比较每项的P≤0.0001)。F1.2值(纳摩尔)与INR呈负相关(F1.2 = -0.1 + 2.3[1/INR];R2 = 0.37;P < 0.0001;简单线性回归)。然而,仍存在显著变异性。在接受华法林治疗的患者中,在模型中对INR强度进行校正后,老年患者的F1.2值高于年轻患者(P < 0.001)。男性和女性在F1.2与INR之间的关系上没有差异。
以INR衡量的抗凝强度增加与以F1.2水平衡量的凝血酶生成减少相关,但这种关系存在显著变异性。在相同INR值时,接受抗凝治疗的老年患者的F1.2值高于年轻患者。这些差异的临床意义尚不清楚。F1.2测量可能除了提供INR所反映的信息外,还能提供有关抗凝强度的信息。